Evaluation of a new prognostic score (Munich score) to predict long-term survival after resection of pulmonary renal cell carcinoma metastases

American Journal of Surgery

Volumn 202, Issue 2, 2011, Pages 158-167

  Meimarakis, Georgios ^a   Angele, Martin ^a   Staehler, Michael ^a   Clevert, Dirk Andre ^a   Crispin, Alexander ^a   Rüttinger, Dominik ^a   Löhe, Florian ^a   Preissler, Gerhard ^a   Hatz, Rudolf A ^a   Winter, Hauke ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Prognostic factors; Pulmonary metastases; Renal cell carcinoma; Surgical resection; Survival

Indexed keywords

ADULT; ARTICLE; CANCER SIZE; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; METASTASIS RESECTION; MUNICH SCORE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL TIME;

ADULT; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; LUNG NEOPLASMS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS;

EID: 79961009657     PISSN: 00029610     EISSN: 18791883     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2010.06.029     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993;54:594-606.
3. McCredie M. Bladder and kidney cancers. Cancer Surv 1994;19-20:343-68. (Pubitemid 24289393)
4. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. The International Registry of Lung Metastases. J Thorac Cardiovasc Surg 1997;113:37-49.
5. Hofmann HS, Neef H, Krohe K, et al. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol 2005;48:77-81. (Pubitemid 40835595)
6. deKernion JB, Ramming KP, Smith RB. The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 1978;120:148-152.
7. Chow WH, Devesa SS, Warren JL, et al. Rising incidence of renal cell cancer in the United States. JAMA 1999;281:1628-31. (Pubitemid 29211773)
8. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001;166:1611-23.
9. Kroger MJ, Menzel T, Gschwend JE, et al. Life quality of patients with metastatic renal cell carcinoma and chemo-immunotherapy - a pilot study. Anticancer Res 1999;19:1553-5.
10. Ravaud A, Audhuy B, Gomez F, et al; Groupe Francais d'Immunotherapie. Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. J Clin Oncol 1998;16:2728-32. (Pubitemid 28363037)
11. Fossa SD, Kramar A, Droz JP. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer 1994;30A:1310-4. (Pubitemid 24322068)
12. Lokich J. Spontaneous regression of metastatic renal cancer. Case report and literature review. Am J Clin Oncol 1997;20:416-8. (Pubitemid 27329580)
13. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133-41. (Pubitemid 41702632)
14. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clearcell renal-cell carcinoma. N Engl J Med 2007;356:125-34. (Pubitemid 46089673)
15. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24. (Pubitemid 46089672)
16. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81. (Pubitemid 46849157)
17. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-11. (Pubitemid 350296300)
18. Friedel G, Hurtgen M, Penzenstadler M, et al. Resection of pulmonary metastases from renal cell carcinoma. Anticancer Res 1999;19:1593-6. (Pubitemid 29255654)
19. Dernevik L, Berggren H, Larsson S, et al. Surgical removal of pulmonary metastases from renal cell carcinoma. Scand J Urol Nephrol 1985;19:133-7. (Pubitemid 15024650)
20. Cerfolio RJ, Allen MS, Deschamps C, et al. Pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 1994;57:339-44. (Pubitemid 24101129)
21. Pogrebniak HW, Haas G, Linehan WM, et al. Renal cell carcinoma: resection of solitary and multiple metastases. Ann Thorac Surg 1992;54:33-8.
22. Piltz S, Meimarakis G, Wichmann MW, et al. Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Surg 2002;73:1082-7. (Pubitemid 34275883)
23. Dineen MK, Pastore RD, Emrich LJ, et al. Results of surgical treatment of renal cell carcinoma with solitary metastasis. J Urol 1988;140:277-9.
24. Fourquier P, Regnard JF, Rea S, et al. Lung metastases of renal cell carcinoma: results of surgical resection. Eur J Cardiothorac Surg 1997;11:17-21. (Pubitemid 27076108)
25. Kavolius JP, Mastorakos DP, Pavlovich C, et al. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998;16:2261-6. (Pubitemid 28265066)
26. Pfannschmidt J, Hoffmann H, Muley T, et al. Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 2002;74:1653-7. (Pubitemid 35222660)
27. Murthy SC, Kim K, Rice TW, et al. Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma? Ann Thorac Surg 2005;79:996-1003.
28. Jett JR, Hollinger CG, Zinsmeister AR, et al. Pulmonary resection of metastatic renal cell carcinoma. Chest 1983;84:442-5. (Pubitemid 14233056)
29. Morrow CE, Vassilopoulos PP, Grage TB. Surgical resection for metastatic neoplasms of the lung: experience at the University of Minnesota Hospitals. Cancer 1980;45:2981-5.
30. Johnsen JA, Hellsten S. Lymphatogenous spread of renal cell carcinoma: an autopsy study. J Urol 1997;157:450-3. (Pubitemid 27026814)
31. Loehe F, Kobinger S, Hatz RA, et al. Value of systematic mediastinal lymph node dissection during pulmonary metastasectomy. Ann Thorac Surg 2001;72:225-9. (Pubitemid 32643041)
32. Pfannschmidt J, Klode J, Muley T, et al. Nodal involvement at the time of pulmonary metastasectomy: experiences in 245 patients. Ann Thorac Surg 2006;81:448-54. (Pubitemid 43120533)
33. Ercan S, Nichols FC III, Trastek VF, et al. Prognostic significance of lymph node metastasis found during pulmonary metastasectomy for extrapulmonary carcinoma. Ann Thorac Surg 2004;77:1786-91. (Pubitemid 38530026)
34. Kandioler D, Kromer E, Tuchler H, et al. Long-term results after repeated surgical removal of pulmonary metastases. Ann Thorac Surg 1998;65:909-12.
35. Maldazys JD, deKernion JB. Prognostic factors in metastatic renal carcinoma. J Urol 1986;136:376-9. (Pubitemid 16070450)
36. Robert JH, Ambrogi V, Mermillod B, et al. Factors influencing longterm survival after lung metastasectomy. Ann Thorac Surg 1997;63:777-84. (Pubitemid 27128700)